Please login to the form below

Not currently logged in
Email:
Password:

Sanofi appoints Bill Sibold to lead its Genzyme business

He will succeed David Meeker, who is leaving in the firm in June

Sanofi_Genzyme_Bill_SiboldSanofi has appointed Bill Sibold as executive vice president for Sanofi Genzyme in a move that will also see he join the company's executive committee.

Previously head of Sanofi Genzyme’s multiple sclerosis, oncology and immunology organisation, Sibold has experience in leading global therapy launches.

Prior to Sanofi, Sibold has held a number of leadership positions for biopharmaceutical companies such as Biogen, Avanir Pharmaceuticals and Eli Lilly.

Oliver Brandicourt, chief executive officer at Sanofi, said: “With a strong commitment to serving patients, Sanofi Genzyme has evolved from a rare disease company into a preeminent specialty care business, deeply rooted in science.

“I am confident in Bill’s experience and leadership to build on this strong foundation as we chart the next chapter for Sanofi Genzyme, which has become a real growth driver for Sanofi.”

Sibold will succeed David Meeker, who will leave the company at the end of June.

7th April 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected healthcare organisations to create powerful digital experiences. We help our...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics